CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients.
CYFRA 21-1 and ProGRP, tumor markers of lung cancer, are elevated in chronic renal failure patients.
复制标题
DOI：
10.1111/j.1440-1843.1998.tb00123.x
复制
发表时间：
1998-09-01
期刊：
影响因子：
--
通讯作者：
Sugita, M
中科院分区：
文献类型：
--
作者：
Nakahama, H;Tanaka, Y;Sugita, M
采用ELISA（酶联免疫吸附法）检测了27例（CYFRA 21-1，男13例，女14例，年龄54+/-17岁）或22例（ProGRP，男9例，女13例，年龄59+/-18岁）不同血清肌酐水平的患者和42例血液透析（HD）患者（男24例，女18例，年龄59+/-18岁）的血清CYFRA 21-1（细胞角蛋白-19片段）和ProGRP（前胃泌素释放肽）的血清水平。年龄59+/-14岁)和30例连续动态腹膜透析（CAPD）患者（男18例，女12例；年龄48+/-9岁）。所有患者均无肺癌临床及影像学征象。血清肌酐、血清CYFRA 21-1和ProGRP水平呈正相关。57%的HD患者（平均4.07+/-1.56 ng/mL）和73%的CAPD患者（平均4.87+/-1.56 ng/mL）血清CYFRA 21-1水平高于临界值（3.5 ng/mL）。90%的HD患者（平均107.0+/-59.4 pg/mL）和93%的CAPD患者（平均112.4+/-44.5 pg/mL）血清ProGRP水平高于临界值（46.0 pg/mL）。我们的数据表明，当这些肿瘤标志物的测量被用作肺癌的诊断工具之一时，肾功能的评估是必不可少的。
Serum levels of CYFRA 21-1(cytokeratin-19 fragment) and ProGRP (pro-gastrin-releasing peptide), the new prognostic markers of lung cancer, were measured by ELISA (enzyme-linked immunoadsorbent assay) in 27 (for CYFRA 21-1; male 13, female 14; age 54+/-17 years) or 22 (for ProGRP; male 9, female 13; age 59+/-18 years) patients with various serum creatinine levels, 42 haemodialysis (HD) patients (male 24, female 18; age 59+/-14 years) and 30 continuous ambulatory peritoneal dialysis (CAPD) patients (male 18, female 12; age 48+/-9 years). All the patients were without clinical and radiological signs of lung cancer. Positive correlations were found between serum creatinine and serum CYFRA 21-1 and ProGRP levels. Serum levels of CYFRA 21-1 were above the cutoff limit (3.5 ng/mL) in 57% of HD patients (mean 4.07+/-1.56 ng/mL) and in 73% of CAPD patients (mean 4.87+/-1.56 ng/mL). Serum levels of ProGRP were above the cutoff limit (46.0 pg/mL) in 90% of HD patients (mean 107.0+/-59.4 pg/mL) and in 93% of CAPD patients (mean 112.4+/-44.5 pg/mL). Our data indicate that evaluation of renal function is essential when the measurement of these tumor markers is to be applied as one of the diagnostic tools of lung cancer.